Pharmacist Medication Insights: Galcanezumab (Emgality) for Migraine

Galcanezumab-gnlm (Emgality) is a CGRP antagonist indicated in adults for the preventive treatment of migraine and treatment of episodic cluster headache.

Galcanezumab-gnlm (Emgality) is a calcitonin-gene related peptide (CGRP) antagonist indicated in adults for the preventive treatment of migraine and treatment of episodic cluster headache.

Galcanezumab-gnlm was approved by the FDA in September 2018 for the preventive treatment of migraine in adults. The drug selectively binds to the CGRP and is the only CGRP monoclonal antibody with response rates in the episodic migraine headache population of ≥50%, ≥75%, and 100% reduction from baseline in monthly migraine headache days over months 1 to 6.

Galcanezumab-gnlm was approved by the FDA in June 2019 for the treatment of episodic cluster headache in adults.